The recent investment by a global private equity firm in a Chinese device maker reflects the continuous and rising flow of capital into China's life science sector, a trend that is expected to continue as the interaction between primary and secondary markets expands.
HONG KONG – A German-Japanese effort to develop a first-line therapy for advanced Asian hepatocellular carcinoma (HCC) recently hit an important milestone with the completion of a phase I trial and the launch of phase II development.
HONG KONG – A German-Japanese effort to develop a first-line therapy for advanced Asian hepatocellular carcinoma (HCC) recently hit an important milestone with the completion of a phase I trial and the launch of phase II development.
SUZHOU, China – A recent deal reflects the trend toward personalized medicine and companion diagnostics in China. The first commercial personalized medicine provider in China, Hangzhou-headquartered Denovo Biopharma, recently disclosed that its San Diego subsidiary had acquired late-stage oncology drug enzastaurin from pharmaceutical multinational Eli Lilly and Co.
HONG KONG – The world's largest health care-dedicated investment firm, Orbimed, has secured a $325 million pan-Asia fund to invest in health care markets in the region, particularly in China and India.
